SUCNR1/GPR91 - a potential role in renovascular hypertension

Fri, 04/03/2015 - 14:49

SUCNR1 is the cognate receptor for the Kreb's citric acid cycle intermediate succinate. It is of interest to scientists because it is involved in not only energy metabolism but possibly also in renovascular hypertension, a condition linked to diabetes, renal failure, and atherosclerosis.  This G-protein coupled receptor is most highly expressed in the kidney - predominantly in the proximal tubules. Two signaling pathways have been identified downstream from SUCNR1: a pertussis-toxin-sensitive Gi/Go pathway, as well as a pertussis-toxin-insensitive Gq pathway.

GPR91 Antibody

Immunohistochemistry-Paraffin: GPR91 Antibody [NBP1-00861] - IHC staining of GPR91 in mouse Vas Deferens where strong membrane staining is observed.

Ophthalmologists from Shanghai employed the SUCNR1 antibody in their investigations of diabetic retinopathy pathology with their rat oxygen-induced model system and RNA interference-targeting of SUCNR1 (1).  Their successful knockdown was found to downregulate VEGF mRNA and protein expression as they had predicted. The same group also published follow-up studies examining which downstream pathways were used in the SUCNR1-dependent VEGF release they originally identified (2).  With those studies, they again relied upon the SUCNR1 antibody – this time to allow them to demonstrate that the hyperglycemia they produced then resulted in significant succinate accumulation and activation of the ERK1/2/COX-2/PGE2 pathway. Yang et al used the SUCNR1 antibody in their studies on hypertension and pressure overloading in the heart (3). Through studying SUCNR1 signaling in a pulmonary arterial banding (PAB) model of right ventricle hypertrophy (RVH) in rats, Yang's group provided evidence that SUCNR1 could be a novel therapeutic target for RVH. Furthermore, the SUCNR1 antibody enabled McCreath et al at the CNIC in Madrid to identify SUCNR1 as a dietary energy sensor (4). Their work is intriguing because it suggests that SUCNR1 could be exploited as a obesity regulator and therapeutic.

Novus Biologicals offers SUCNR1 reagents for your research needs including:


  1. 23379999
  2. 25324681
  3. 25337184
  4. 25352636

Blog Topics